NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

I have this uncomfortable feeling that LL et al, have been barking up the wrong tree for the last 5 or 6 years....

Perhaps. But I'd tend to think that they've been categorizing all the patients in this trial as well. And they'd likely done a good deal of that by the time of LL's talk in December 2016, when she put a lot of emphasis on mesenchymal subtypes doing best on DCVax treatment. We may find that a good number of those 100 who did so well are also mesenchymal.

And perhaps Kat and Jeanine were also mesenchymal, because upon recurrence, proneural tumors shift towards becoming more mesenchymal. And they were both treated with DCVax-L upon recurrence. I think Jeanine was treated in 2013, so if there was a change in the transition from P2 to P3, and something like TFF was added, she would have got it.